Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Imugene Limited (IUGNF)
:IUGNF
Holding IUGNF?
Track your performance easily
IUGNF Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.02 - $0.11
Previous CloseN/A
Volume3.00K
Average Volume (3M)126.30K
Market Cap
$180.04M
Enterprise Value$323.08M
Total Cash (Recent Filing)$4.81M
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta0.89
Next Earnings
Feb 26, 2025EPS Estimate
>-0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.01
Shares Outstanding7,456,532,000
10 Day Avg. Volume95,334
30 Day Avg. Volume126,298
Standard Deviation0.42
R-Squared0.22
Alpha0.01
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market Cap1.79
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Imugene Limited News
PremiumCompany Announcements
Imugene Limited Announces New Securities Quotation on ASX
PremiumCompany Announcements
Imugene Secures $11.7m R&D Tax Refund to Boost Cancer Therapy Development
PremiumCompany Announcements
Imugene’s Australian Trial for Innovative Cancer Therapy Begins
PremiumCompany Announcements
Imugene Secures A$46 Million for Clinical TrialsPremiumCompany Announcements
Imugene’s Azer-cel to be Featured at Major Conference
PremiumCompany Announcements
Imugene Limited Secures $11 Million R&D Tax Refund
PremiumCompany Announcements
Imugene Limited Updates and Focus on Cancer Therapies
PremiumCompany Announcements
Imugene Limited Announces Director Change and Stock HoldingsOptions Prices
Currently, No data available
---
Ownership Overview
7.20% Insiders
2.55% Mutual Funds
<0.01% Other Institutional Investors
87.40% Public Companies and
Individual Investors
IUGNF FAQ
What was Imugene Limited’s price range in the past 12 months?
Imugene Limited lowest stock price was $0.01 and its highest was $0.10 in the past 12 months.
What is Imugene Limited’s market cap?
Imugene Limited’s market cap is $180.04M.
When is Imugene Limited’s upcoming earnings report date?
Imugene Limited’s upcoming earnings report date is Feb 26, 2025 which is in 38 days.
How were Imugene Limited’s earnings last quarter?
Imugene Limited released its earnings results on Aug 30, 2024. The company reported -$0.006 earnings per share for the quarter, the consensus estimate of -$0.006 by $0.
Is Imugene Limited overvalued?
According to Wall Street analysts Imugene Limited’s price is currently Overvalued.
Does Imugene Limited pay dividends?
Imugene Limited does not currently pay dividends.
What is Imugene Limited’s EPS estimate?
Imugene Limited’s EPS estimate is >-0.01.
How many shares outstanding does Imugene Limited have?
Imugene Limited has 7,456,532,000 shares outstanding.
What happened to Imugene Limited’s price movement after its last earnings report?
Imugene Limited reported an EPS of -$0.006 in its last earnings report, expectations of -$0.006. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Imugene Limited?
Currently, no hedge funds are holding shares in IUGNF
---
Imugene Limited Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
IUGNF Sentiment 70%
Sector Average 71%
Sector Average 71%
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-68.75%
12-Months-Change
Fundamentals
Return on Equity
-95.64%
Trailing 12-Months
Asset Growth
-22.92%
Trailing 12-Months
Company Description
Imugene Limited
Imugene Ltd specializes is a clinical-stage immuno-oncology company. Its product includes HER-Vaxx, a proprietary HER2 +ve cancer vaccine that stimulates a polyclonal antibody response to HER2/neu. The company is also developing B-cell peptide cancer vaccines and therapeutics. Its only operating segment being Research, Development, and Commercialisation of oncolytic immunotherapies.
---
IUGNF Stock 12 Month Forecast
Average Price Target
―Technical Analysis
Mesoblast Limited
―
Race Oncology Ltd.
―
Telix Pharmaceuticals Ltd.
―
Biotron Limited
―
Proteomics International Laboratories Ltd.
―
Best Analysts Covering IUGNF
1 Year
1 Year Success Rate
0/3 ratings generated profit
1 Year Average Return
-49.43%
reiterated a buy rating 9 months ago
Copying John Hester's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -49.43% per trade.
---